Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 884Precursor Cell Lymphoblastic Leukemia-Lymphoma 509Hematologic Neoplasms 466Leukemia, Lymphocytic, Chronic, B-Cell 391Leukemia 337Myelodysplastic Syndromes 329Lymphoma 208Lymphoma, Non-Hodgkin 191Multiple Myeloma 146Leukemia, Myelogenous, Chronic, BCR-ABL Positive 141Recurrence 138Neoplasms 135Leukemia, Myelomonocytic, Chronic 112Burkitt Lymphoma 93Lymphoma, Mantle-Cell 92Lymphoma, Follicular 92Lymphoma, Large B-Cell, Diffuse 90Myeloproliferative Disorders 84Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 83Leukemia, Biphenotypic, Acute 81Lymphoma, B-Cell, Marginal Zone 75Hodgkin Disease 72Lymphoma, B-Cell 64Waldenstrom Macroglobulinemia 54Primary Myelofibrosis 54Leukemia, B-Cell 52Anemia, Refractory, with Excess of Blasts 46Leukemia, Myeloid, Chronic-Phase 40Hematologic Diseases 37Lymphoma, T-Cell 33

Interventions

gamma-Globulins 1Saline Solution 1Panzyga 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Agammaglobulinemia × Other hematologic neoplasm × 1 year × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05645107 2026-04-13

EXCELL

Grifols Therapeutics LLC

Phase 3 Recruiting
386 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Bacterial Infections, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡